WO2001092219A1 - Glycinamide - Google Patents
Glycinamide Download PDFInfo
- Publication number
- WO2001092219A1 WO2001092219A1 PCT/EP2001/004110 EP0104110W WO0192219A1 WO 2001092219 A1 WO2001092219 A1 WO 2001092219A1 EP 0104110 W EP0104110 W EP 0104110W WO 0192219 A1 WO0192219 A1 WO 0192219A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acetamide
- coo
- biphenyl
- aminosulfonyl
- amidinophenyl
- Prior art date
Links
- HNJOAIYFUCQZAA-UHFFFAOYSA-N Cc1n[o]c(C)n1 Chemical compound Cc1n[o]c(C)n1 HNJOAIYFUCQZAA-UHFFFAOYSA-N 0.000 description 2
- 0 C*C(N1)=NOC1=O Chemical compound C*C(N1)=NOC1=O 0.000 description 1
- RKRLQDJTVWZXMM-UHFFFAOYSA-N CC(N1)=NOC1=O Chemical compound CC(N1)=NOC1=O RKRLQDJTVWZXMM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the invention relates to compounds of the formula
- R 1 unbranched, branched or cyclic alkyl having 1-20 C atoms, in which one or two CH 2 groups can be replaced by O or S atoms, Ar, Ar 'or X,
- R ⁇ simply phenyl substituted by S (0) p A, S (0) p NHA, CF 3 , COOA, CH 2 NHA, CN or OA,
- Ar unsubstituted or mono-, di- or trisubstituted by A, OA, NAA ', N0 2 , CF 3 , CN, shark, NHCOA, COOA, CONAA', S (0) p A, S (0) pNAA ' or naphthyl, Ar '- (CH 2 ) n -Ar,
- the invention also relates to the optically active forms, the racemates, the diastereomers and the hydrates and solvates, e.g. Alcohololates, these compounds.
- the invention was based on the task of finding new compounds with valuable properties, in particular those which can be used for the production of medicaments.
- the compounds of the formula I and their salts have very valuable pharmacological properties with good tolerability.
- they show factor Xa inhibitory properties and can therefore be used to combat and prevent thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication.
- the compounds of the formula I according to the invention can furthermore be inhibitors of the coagulation factors factor VIIa, factor IXa and thrombin of the blood coagulation cascade.
- Aromatic amidine derivatives with antithrombotic activity are e.g. known from EP 0 540 051 B1.
- Cyclic guanidines for the treatment of thromboembolic disorders are e.g. described in WO 97/08165.
- Aromatic heterocycles with factor Xa inhibitory activity are e.g. known from WO 96/10022.
- Substituted N - [(aminoimino-methyl) phenylalkyl] azaheterocyclylamides as factor Xa inhibitors are in
- the antithrombotic and anticoagulant effect of the compounds according to the invention is attributed to the inhibitory action against the activated coagulation protease, known under the name factor Xa, or to the inhibition of other activated serine proteases such as factor VIIa, factor IXa or thrombin.
- Factor Xa is one of the proteases involved in the complex process of blood clotting. Factor Xa catalyzes the conversion of prothrombin to thrombin. Thrombin cleaves fibrinogen into fibrin monomers which, after cross-linking, make an elementary contribution to thrombus formation. Activation of thrombin can lead to the occurrence of thromboembolic disorders. However, inhibition of thrombin can inhibit fibrin formation involved in thrombus formation. The measurement of the inhibition of thrombin can e.g. using the method of G.F. Cousins et al. in Circulation 1996, 94, 1705-1712.
- Inhibition of factor Xa can thus prevent thrombin from being formed.
- the compounds of formula I according to the invention and their salts interfere with the blood coagulation process by inhibiting factor Xa and thus inhibit the formation of thrombi.
- the inhibition of factor Xa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by customary in vitro or in vivo methods. A suitable method is described, for example, by J. Hauptmann et al. in Thrombosis and Haemostasis 1990, 63, 220-223.
- the measurement of the inhibition of factor Xa can e.g. using the method of T. Hara et al. in thromb. Haemostas. 1994, 71, 314-319.
- the coagulation factor VIa initiates the extrinsic part of the coagulation cascade after binding to the tissue factor and contributes to the activation of factor X to factor Xa. Inhibition of factor VIIa thus prevents the formation of factor Xa and thus the subsequent formation of thrombin.
- the inhibition of the factor VIIa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by customary in vitro or in vivo methods.
- a common method for measuring the inhibition of factor VIIa is e.g. by H. F. Ronning et al. in Thrombosis Research 1996, 84, 73-81.
- Coagulation factor IXa is generated in the intrinsic coagulation cascade and is also involved in the activation of factor X to factor Xa. Inhibition of factor IXa can therefore otherwise prevent factor Xa from being formed.
- the inhibition of factor IXa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by customary in vitro or in vivo methods.
- a suitable method is e.g. by J. Chang et al. in Journal of Biological Chemistry 1998, 273, 12089-12094.
- the invention relates to the compounds of the formula I according to claims 1 to 2 and to their physiologically acceptable salts and solvates as medicaments.
- the compounds of formula I can be used as active pharmaceutical ingredients in human and veterinary medicine, in particular for combating and preventing thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudication intermediate ,
- the invention therefore also relates to the pharmaceutical active substances mentioned as inhibitors of the coagulation factor Xa and to these medicaments for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication.
- the invention relates to the compounds of the formula I and their salts and to a process for the preparation of compounds of the formula I according to claim 1, in which R is amidino, and their salts, characterized in that
- Trt trityl (triphenylmethyl).
- Alkyl is unbranched (linear) or branched, and has 1 to 20, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms.
- Alkyl preferably means methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, further also pentyl, 1-, 2- or 3-methylbutyl, 1, 1-, 1, 2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1, 1-, 1, 2-, 1, 3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1, 1, 2- or 1, 2,2-trimethylpropyl, more preferably e.g.
- Trifluoromethyl A very particularly preferably denotes alkyl having 1-6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl.
- Cyclic alkyl or cycloalkyl preferably means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
- Shark preferably means F, Cl or Br, but also Ar means unsubstituted or single, double or triple by A, OA, NAA ', N0 2 , CF 3 , CN, Hai, NHCOA, COOA, CONAA', S (0) p A, S (0) p NAA ' substituted phenyl or naphthyl.
- Preferred substituents for phenyl or naphthyl are, for example, methyl, ethyl, propyl, butyl, OH, methoxy, ethoxy, propoxy, butoxy, amino, methylamino, dimethylamino, ethylamino, diethylamino, nitro, trifluoromethyl, fluorine, chlorine, acetamido, methoxycarbonyl, Ethoxycarbonyl, aminocarbonyl, sulfonamido, methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, tert.-butylsulfonamido, tert.-butylaminosulfonyl, dimethylsulfonamido, phenylsulfonamido, carboxy, propylsulfonamyl, acylocyl,
- Ar particularly preferably means, for example, unsubstituted phenyl or simply phenyl substituted by SO2NH2, SO2CH 3 , fluorine or alkoxy, such as methoxy.
- Ar 'means - (CH 2 ) n -Ar preferably unsubstituted or mono-, di- or trisubstituted by fluorine and / or chlorine-substituted benzyl.
- Y preferably means e.g. Methoxycarbonyl, ethoxycarbonyl or 1-methyl-tetrazol-5-yl.
- n is preferably e.g. 1 or 2.
- Het preferably means e.g. 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2 -, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2 -, 4-, 5- or 6-pyrimidinyl, further preferably 1, 2,3-triazoM-, -4- or -5-yl, 1, 2,4-triazol-1-, -3- or 5-yl , 1- or 5-tetrazolyl, 1, 2,3-oxadiazol-4- or -5-yl, 1, 2,4-oxadiazol-3- or - 5-yl, 1, 3,4-thiadiazol-2- or -5-yl, 1, 2,4-thiadiazol-3- or -5-yl, 1, 2,3-
- Het can, for. B. also mean 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2 - or -3-furyl, 1, 3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1 -, -2-, -3-, -4- or -5-pyrrolyl, 1 -, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2 - or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl,
- Het particularly preferably means e.g. Furyl, thienyl, thiazolyl, imidazolyl, [2,1, 3] -benzothiadiazolyl, oxazolyl, pyridyl, indolyl, 1-methyl-piperidinyl, piperidinyl or pyrrolidinyl, pyridyl, 1-methyl-piperidin-4- is very particularly preferred yl or piperidin-4-yl.
- R 1 preferably means, for example, benzyl, methyl, ethyl, propyl, butyl, iso-
- R 2 preferably means, for example, phenyl which is simply substituted by S0 2 NH 2 or S0 2 Me.
- the compounds of the formula I can have one or more chiral centers and therefore exist in various stereoisomeric forms.
- Formula I encompasses all of these forms.
- the invention relates in particular to those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above.
- Some preferred groups of compounds can be expressed by the following sub-formulas Ia to Ih, which correspond to the formula I and in which the radicals not specified have the meaning given for the formula I, but in which
- R 1 unbranched, branched or cyclic alkyl with 1-8
- R 1 unbranched, branched or cyclic alkyl with 1-8
- CN or OA is substituted phenyl
- R 1 unbranched, branched or cyclic alkyl with 1-8
- R 2 simply by S0 2 A, S0 2 NHA, CF 3 , COOA, CH 2 NHA,
- R 1 unbranched, branched or cyclic alkyl with 1-8
- R 2 simply by S0 2 A, S0 2 NHA, CF 3 , COOA, CH 2 NHA,
- R 1 unbranched, branched or cyclic alkyl with 1-8
- R 2 simply by S0 2 A, S0 2 NHA, CF 3 , COOA, CH 2 NHA,
- R 1 unbranched, branched or cyclic alkyl with 1-8
- R 2 is simply phenyl substituted by S0 2 A, S0 2 NHA, CF 3 , COOA, CH 2 NHA, CN or OA,
- R 1 unbranched, branched or cyclic alkyl with 1-8
- R 2 is simply phenyl substituted by S0 2 A, S0 2 NHA, CF 3 , COOA, CH 2 NHA, CN or OA,
- Ar unsubstituted or mono-, di- or trisubstituted by fluorine-substituted benzyl, A, A 'each independently of one another H, unbranched, branched or cyclic alkyl having 1-8 C atoms,
- Het is a mononuclear saturated or aromatic heterocycle with 1 to 2 N and / or O atoms
- the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula I.
- Compounds of formula I can preferably be obtained by liberating compounds of formula I from one of their functional derivatives by treatment with a solvolysing or hydrogenolysing agent.
- Preferred starting materials for solvolysis or hydrogenolysis are those which otherwise correspond to the formula I, but instead of one or more free amino and / or hydroxyl groups contain corresponding protected amino and / or hydroxyl groups, preferably those which instead of an H atom, which is connected to an N atom carry an amino protective group, in particular those which carry an R'-N group instead of an HN group, in which R 'represents an amino protective group, and / or those which have one instead of the H atom Hydroxy group carry a hydroxyl protective group, for example those which have the formula! correspond - lo ⁇
- chen but instead of a group -COOH carry a group -COOR ", in which R" denotes a hydroxy protective group.
- Preferred starting materials are also the oxadiazole derivatives, which can be converted into the corresponding amidino compounds.
- the release of the amidino group from its oxadiazole derivative can e.g. by treatment with hydrogen in the presence of a catalyst (e.g. water-moist Raney nickel).
- a catalyst e.g. water-moist Raney nickel
- Suitable solvents are those specified below, in particular alcohols such as methanol or ethanol, organic acids such as acetic acid or propionic acid or mixtures thereof.
- the hydrogenolysis is generally carried out at temperatures between about 0 and 100 ° and pressures between about 1 and 200 bar, preferably at 20-30 ° (room temperature) and 1-10 bar.
- the introduction of the oxadiazole group succeeds e.g. by reaction of the cyan compounds with hydroxylamine and reaction with phosgene, dialkyl carbonate, chloroformate, N, N'-carbonyldiimidazole or acetic anhydride.
- amino protecting group is generally known and refers to groups which are suitable for protecting (blocking) an amino group from chemical reactions, but which are easily removable after the desired chemical reaction has been carried out at other locations in the molecule. Unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups are particularly typical of such groups. Since the amino protective groups are removed after the desired reaction (or reaction sequence), their type and size is otherwise not critical; however, preference is given to those having 1-20, in particular 1-8, carbon atoms.
- acyl group is to be understood in the broadest sense in connection with the present process.
- He um- includes acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids and in particular alkoxycarbonyl, aryloxycarbonyl and especially aralkoxycarbonyl groups.
- acyl groups are alkanoyl such as acetyl, propionyl, butyryl; Aralkanoyl such as phenylacetyl; Aroyl such as benzoyl or toluyl; Aryloxyalkanoyl such as POA; Alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC (tert-butyloxycarbonyl), 2-iodoethoxycarbonyl; Aralkyloxycarbonyl such as CBZ ("carbobenzoxy"), 4-methoxybenzyloxycarbonyl, FMOC; Arylsulfonyl such as Mtr.
- Preferred amino protective groups are BOC and Mtr, furthermore CBZ, Fmoc, benzyl and acetyl.
- Suitable inert solvents are preferably organic, for example carboxylic acids such as acetic acid, ethers such as tetrahydrofuran or dioxane, amides such as DMF, halogenated hydrocarbons such as dichloromethane, and also alcohols such as methanol, ethanol or isopropanol, and water. Mixtures of the abovementioned solvents are also suitable. TFA is preferably used in excess without the addition of another solvent, perchloric acid in the form of a mixture of acetic acid and 70% perchloric acid in a ratio of 9: 1.
- the reaction temperatures for the cleavage are advantageously between about 0 and about 50 °, preferably between 15 and 30 ° (room temperature).
- the groups BOC, OBut and Mtr can e.g. B. preferably with TFA in dichloromethane or with about 3 to 5N HCl in dioxane at 15-30 °, the FMOC group with an about 5 to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15-30 °.
- Hydrogenolytically removable protective groups e.g. CBZ, benzyl or the release of the amidino group from their oxadiazole derivative
- a catalyst z. B. a noble metal catalyst such as palladium, advantageously on a support such as coal.
- Suitable solvents are the above, especially z. B.
- the hydrogenolysis is generally carried out at temperatures between about 0 and 100 ° and pressures between about 1 and 200 bar, preferably at 20-30 ° and 1-10 bar.
- Hydrogenolysis of the CBZ group succeeds e.g. B. good on 5 to 10% Pd / C in methanol or with ammonium formate (instead of hydrogen) on Pd / C in metha ⁇ ol / DMF at 20-30 °.
- Suitable inert solvents are e.g. Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, trifluoromethylbenzene, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Amides such as acetamide, dimethylacetamide
- An S0 2 NH 2 group for example in R 2 , is preferably used in the form of its tert-butyl derivative.
- the tert-butyl group is split off, for example, using TFA with or without the addition of an inert solvent, preferably with the addition of a small amount of anisole (1-10% by volume).
- the conversion of a cyano group into an amidino group takes place by reaction with, for example, hydroxylamine and subsequent reduction of the N- Hydroxyamidine with hydrogen in the presence of a catalyst such as Pd / C.
- ammonia can also be added to a nitrile.
- the addition is preferably carried out in several stages by, in a manner known per se, a) converting the nitrile with H 2 S into a thioamide, which is converted into the corresponding S-alkylimidothioester using an alkylating agent, for example CH 3 I, which in turn contains NH 3 reacts to the amidine, b) the nitrile is converted to the corresponding imidoester with an alcohol, for example ethanol in the presence of HCl, and treated with ammonia, or c) the nitrile is reacted with lithium bis (trimethylsilyl) amide and the product then hydrolyzed.
- an alkylating agent for example CH 3 I
- R 1 has the meaning given in claim 1 and L is Cl, Br, I or a free or reactive functional OH group,
- R has the meaning given in claim 1, but a free NH 2 or OH group is substituted by a protective group.
- L is preferably Cl, Br, I or a free or reactively modified OH group such as e.g. an activated ester, an imidazolide or alkylsulfonyloxy with 1-6 C atoms (preferably methylsulfonyloxy) or arylsulfonyloxy with 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy).
- a free or reactively modified OH group such as e.g. an activated ester, an imidazolide or alkylsulfonyloxy with 1-6 C atoms (preferably methylsulfonyloxy) or arylsulfonyloxy with 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy).
- the precursors of the compounds of the formula I can be prepared by reacting compounds of the formula IV
- R 2 has the meaning given in claim 1, but a free NH 2 or OH group is substituted by a protective group.
- L preferably denotes Cl, Br, I or a free or reactive modified OH group such as e.g. an activated ester, an imidazolide or alkylsulfonyloxy with 1-6 C atoms (preferably methylsulfonyloxy) or arylsulfonyloxy with 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy).
- a free or reactive modified OH group such as e.g. an activated ester, an imidazolide or alkylsulfonyloxy with 1-6 C atoms (preferably methylsulfonyloxy) or arylsulfonyloxy with 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy).
- Amine components of the formula III or IV are preferably carried out in a manner known per se in a protic or aprotic polar or non-polar inert organic solvent.
- Some of the compounds of the formulas II, III, IV and V used as intermediates are known or can be prepared by customary methods.
- a preferred variant also consists in reacting the reactants directly with one another without the addition of a solvent.
- Suitable bases are preferably e.g. Alkali metal or alkaline earth metal hydroxides, carbonates, alcoholates or organic bases such as triethylamine or pyridine, which are also used in excess and can then simultaneously serve as solvents.
- Alcohols such as methanol, ethanol, isopropanol, n-butanol or tert-butanol are particularly suitable as inert solvents; Ethers such as diethyl ether, diisopropyl ether, THF or dioxane; Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Nitriles such as acetonitrile; Nitro compounds such as nitromethane or nitrobenzene; Esters such as ethyl acetate; Amides such as phosphoric acid hexamethyl triamide; Sulfoxides such as dimethyl sulfoxide (DMSO); chlorinated hydrocarbons such as dichloromethane, chloroform, trichlorethylene, 1, 2-dichloroethane or carbon tetrachloride; Hydrocarbon
- Particularly suitable solvents are methanol, THF, dimethoxyethane, dioxane, water or mixtures which can be prepared therefrom.
- temperatures between 20 ° and the boiling point of the solvent are suitable as the reaction temperature.
- the reaction times are between 5 minutes and 30 hours.
- an acid scavenger in the reaction.
- Any type of base that does not interfere with the reaction itself is suitable for this.
- the use of inorganic bases such as potassium carbonate or of organic bases such as triethylamine or pyridine is particularly suitable.
- Esters can be saponified, for example, with acetic acid or with NaOH or KOH in water, water-THF or water-dioxane at temperatures between 0 and 100 °.
- free amino groups can be acylated in the usual way with an acid chloride or anhydride or alkylated with an unsubstituted or substituted alkyl halide, advantageously in an inert solvent such as dichloromethane or THF and / or in the presence of a base such as triethylamine or pyridine at temperatures between -60 and + 30 °.
- a base of the formula I can be converted into the associated acid addition salt using an acid, for example by reacting equivalent amounts of the base and the acid in an inert solvent such as ethanol and subsequent evaporation.
- acids that provide physiologically acceptable salts are suitable for this implementation.
- So inorganic acids can be used, e.g. Sulfuric acid, nitric acid, hydrogen halide acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g.
- compounds of the formula I with bases for example sodium or potassium hydroxide or carbonate
- bases for example sodium or potassium hydroxide or carbonate
- compounds of the formula I with bases can be used in the corresponding metal, in particular special alkali metal or alkaline earth metal, or be converted into the corresponding ammonium salts.
- physiologically harmless organic bases e.g. Ethanolamine can be used.
- the pharmaceutical activity of the racemates or the stereoisomers of the compounds according to the invention can differ, it may be desirable to use the enantiomers.
- the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or can already be used as such in the synthesis.
- diastereomers are formed from the mixture by reaction with an optically active release agent.
- Suitable release agents are e.g. optically active acids, such as the R and S forms of tartaric acid, diacetytartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (e.g. N-benzoylproline or N-benzenesulfonylproline) or the various optically active camphorsulfonic acids.
- optically active acids such as the R and S forms of tartaric acid, diacetytartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (e.g. N-benzoylproline or N-benzenesulfonylproline) or the various optically active camphorsulfonic acids.
- Aqueous or alcoholic solvent mixtures such as e.g. Hexane / isopropanol / acetonitrile e.g. in the ratio 82: 15: 3.
- the invention furthermore relates to the use of the compounds of the formula I and / or their physiologically acceptable salts for the production of pharmaceutical preparations, in particular by a non-chemical route.
- they can be combined with at least one solid, liquid and / or semi-liquid carrier or auxiliary and if necessary, be brought into a suitable dosage form in combination with one or more further active ingredients.
- the invention thus also relates to pharmaceutical preparations containing at least one medicament according to one of claims 5 to 6 and, if appropriate, carriers and / or auxiliaries and, if appropriate, other active compounds.
- Suitable carriers are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical application and do not react with the new compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin , Carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly.
- tablets, pills, dragees, capsules, powders, granules, syrups, juices or drops are used, for rectal use suppositories, for parenteral use, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants, for topical use Ointments, creams or powder.
- the new compounds can also be lyophilized and the lyophilizates obtained e.g. can be used for the production of injectables.
- the specified preparations can be sterilized and / or contain auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, flavoring and / or several other active substances, eg one or more vitamins.
- auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, flavoring and / or several other active substances, eg one or more vitamins.
- the invention also relates to the use of compounds according to claims 1 to 2 and / or their physiologically acceptable salts for the manufacture of a medicament for combating thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis Intermittent angioplasty and claudication
- thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis Intermittent angioplasty and claudication
- the substances according to the invention are generally preferably used in doses between about 1 and 500 mg, in particular between 5 and 100 mg per dosage unit administered.
- the daily dosage is preferably between about 0.02 and 10 mg / kg body weight.
- the specific dose for each patient depends on a wide variety of factors, for example on the effectiveness of the particular compound used, on the age, body weight, general health, sex, on the diet, on the time and route of administration, on the rate of elimination and combination of drugs and severity of the respective disease to which the therapy applies. Oral application is preferred.
- Example 6 The implementation is analogous to SM Rahmathullah et al. in J. Med. Chem. 1999, 42, 3994-4000.
- compound 2 is obtained by reacting 3- / - [3- (5-methyl- [1,2,4] oxadiazol-3-yl) phenyl] -2,2,2-trifluoroacetamide by reaction with ethyl bromoacetate - [3- (5-Methyl- [1, 2,4] oxadiazol-3-yl) phenylamino] acetic acid ethyl ester and further analogously as described above the compound ⁇ / - (2'-methylsulfonyl-biphenyl-4- yl) -2 - [(3-amidinophenyl) -N- (ethoxycarbonylmethyl) amino] acetamide.
- Example A Injection glasses
- a solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized under sterile conditions and sealed sterile. Each injection jar contains 5 mg of active ingredient.
- a mixture of 20 g of an active ingredient of the formula I is melted with 100 g of soy lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool. Each suppository contains 20 mg of active ingredient.
- a solution of 1 g of an active ingredient is prepared of the formula I, 9.38 g of NaH 2 P0 4 • 2 H 2 0, 28.48 g Na 2 HP0 4 • 12 H 2 0 and 0.1 g of benzalkonium chloride in 940 ml of double distilled water. It is adjusted to pH 6.8, made up to 1 I and sterilized by irradiation. This solution can be used in the form of eye drops.
- Example D ointment
- 500 mg of an active ingredient of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.
- Example F coated tablets
- Example E tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
- Example G capsules
- each capsule contains 20 mg of the active ingredient.
- a solution of 1 kg of active ingredient of the formula I in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each ampoule contains 10 mg of active ingredient.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01933811A EP1284961A1 (de) | 2000-05-31 | 2001-04-10 | Glycinamide |
JP2002500834A JP2003535075A (ja) | 2000-05-31 | 2001-04-10 | グリシンアミド |
CA002410627A CA2410627A1 (en) | 2000-05-31 | 2001-04-10 | Glycinamides |
AU2001260192A AU2001260192A1 (en) | 2000-05-31 | 2001-04-10 | Glycinamides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10027025.5 | 2000-05-31 | ||
DE10027025A DE10027025A1 (de) | 2000-05-31 | 2000-05-31 | Clycinamide |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001092219A1 true WO2001092219A1 (de) | 2001-12-06 |
Family
ID=7644255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/004110 WO2001092219A1 (de) | 2000-05-31 | 2001-04-10 | Glycinamide |
Country Status (7)
Country | Link |
---|---|
US (1) | US20030166694A1 (de) |
EP (1) | EP1284961A1 (de) |
JP (1) | JP2003535075A (de) |
AU (1) | AU2001260192A1 (de) |
CA (1) | CA2410627A1 (de) |
DE (1) | DE10027025A1 (de) |
WO (1) | WO2001092219A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002030880A2 (de) * | 2000-10-13 | 2002-04-18 | Merck Patent Gmbh | N-SUBSTITUIERTE AMINOSÄUREDERIVATE (FAKTOR Xa INHIBITOREN) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10214832A1 (de) * | 2002-04-04 | 2003-10-16 | Merck Patent Gmbh | Phenylderivate 4 |
US20040180893A1 (en) * | 2003-02-21 | 2004-09-16 | Balzarini Jan Maria Rene | Identification of compounds that inhibit replication of human immunodeficiency virus |
US20050096319A1 (en) * | 2003-02-21 | 2005-05-05 | Balzarini Jan M.R. | Identification of compounds that inhibit replication of human immunodeficiency virus |
AR054321A1 (es) * | 2005-01-10 | 2007-06-20 | Bristol Myers Squibb Co | Derivados en fenilglicinamida utiles como anticoagulantes |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997030971A1 (en) * | 1996-02-22 | 1997-08-28 | The Du Pont Merck Pharmaceutical Company | M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS |
WO1998028282A2 (en) * | 1996-12-23 | 1998-07-02 | Du Pont Pharmaceuticals Company | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS |
WO1999010361A1 (fr) * | 1997-08-26 | 1999-03-04 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Oligonucleotides permettant l'identification de precurseurs d'hormones polypeptidiques amidees |
EP1020434A1 (de) * | 1997-08-27 | 2000-07-19 | Kissei Pharmaceutical Co., Ltd. | 3-amidinoanilin-derivate, inhibitoren des aktivierten blutgerinnungsfaktors x und zwischenpodukte zur herstellung beider |
WO2000071507A2 (en) * | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
-
2000
- 2000-05-31 DE DE10027025A patent/DE10027025A1/de active Pending
-
2001
- 2001-04-10 JP JP2002500834A patent/JP2003535075A/ja active Pending
- 2001-04-10 AU AU2001260192A patent/AU2001260192A1/en not_active Abandoned
- 2001-04-10 CA CA002410627A patent/CA2410627A1/en not_active Abandoned
- 2001-04-10 EP EP01933811A patent/EP1284961A1/de not_active Withdrawn
- 2001-04-10 WO PCT/EP2001/004110 patent/WO2001092219A1/de not_active Application Discontinuation
- 2001-04-10 US US10/296,751 patent/US20030166694A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997030971A1 (en) * | 1996-02-22 | 1997-08-28 | The Du Pont Merck Pharmaceutical Company | M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS |
WO1998028282A2 (en) * | 1996-12-23 | 1998-07-02 | Du Pont Pharmaceuticals Company | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS |
WO1999010361A1 (fr) * | 1997-08-26 | 1999-03-04 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Oligonucleotides permettant l'identification de precurseurs d'hormones polypeptidiques amidees |
EP1020434A1 (de) * | 1997-08-27 | 2000-07-19 | Kissei Pharmaceutical Co., Ltd. | 3-amidinoanilin-derivate, inhibitoren des aktivierten blutgerinnungsfaktors x und zwischenpodukte zur herstellung beider |
WO2000071507A2 (en) * | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002030880A2 (de) * | 2000-10-13 | 2002-04-18 | Merck Patent Gmbh | N-SUBSTITUIERTE AMINOSÄUREDERIVATE (FAKTOR Xa INHIBITOREN) |
WO2002030880A3 (de) * | 2000-10-13 | 2002-10-03 | Merck Patent Gmbh | N-SUBSTITUIERTE AMINOSÄUREDERIVATE (FAKTOR Xa INHIBITOREN) |
Also Published As
Publication number | Publication date |
---|---|
US20030166694A1 (en) | 2003-09-04 |
EP1284961A1 (de) | 2003-02-26 |
JP2003535075A (ja) | 2003-11-25 |
DE10027025A1 (de) | 2001-12-06 |
CA2410627A1 (en) | 2002-11-28 |
AU2001260192A1 (en) | 2001-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1025086B1 (de) | Benzamidinderivate als faktor xa-inhibitoren | |
DE10063008A1 (de) | Carbonsäureamidderivate | |
DE10102322A1 (de) | Phenylderivate | |
EP1558247A1 (de) | Benzimidazolderivate | |
DE10112768A1 (de) | Phenylderivate 3 | |
WO2004002477A1 (de) | 2-(phenyl)-2h-pyrazol-3-carbonsäure-n-4-(thioxo-heterocyclyl)-phenyl-amid derivate und entsprechende imino-heterocyclyl derivate sowie verwandte verbindungen als inhibitoren der koagulationsfaktoren xa und/oder viia zur behandlung bon thrombosen | |
WO2000051989A1 (de) | Pyrazol-3-on-derivate als faktor xa inhibitoren | |
DE10117823A1 (de) | Oxalsäurederivate | |
DE10155075A1 (de) | Cyclische Sulfonamide | |
WO2003084533A1 (de) | N-`4-(2-imino-pyrrolidin-1-yl)phenyl!-acetemid-und entsprechende piperidinderivate als faktor xa inhibitoren zur behandlung von thromboembolischen erkrankungen | |
EP1284961A1 (de) | Glycinamide | |
DE10035144A1 (de) | Cyclische Aminosäurederivate | |
WO2003013531A1 (de) | Phenylderivate als faktor xa inhibitoren | |
WO2002074735A2 (de) | Biurethanderivate | |
EP1303482A2 (de) | N-substituierte-1-amino-1,1-dialkylcarbonsäurederivate | |
EP1585730A1 (de) | Carbonsäureamidderivate und ihre verwendung als faktor xa inhibitoren | |
DE10110325A1 (de) | Phenylderivate 2 | |
WO2001092214A1 (de) | Carbaminsäureester als inhibitoren des faktors xa | |
WO2002010127A1 (de) | Acetamidderivate und ihre verwendung als inhibitoren des koagulationsfaktors xa und viia | |
EP1309573A1 (de) | Urethanderivate | |
EP1480948A1 (de) | Semicarbazidderivate und ihre verwendung als antithrombotika |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EE ES GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001933811 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10296751 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2410627 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2002 500834 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2001933811 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001933811 Country of ref document: EP |